CN1282473C - Wild chrysanthemum granules and preparation method - Google Patents

Wild chrysanthemum granules and preparation method Download PDF

Info

Publication number
CN1282473C
CN1282473C CN 02132705 CN02132705A CN1282473C CN 1282473 C CN1282473 C CN 1282473C CN 02132705 CN02132705 CN 02132705 CN 02132705 A CN02132705 A CN 02132705A CN 1282473 C CN1282473 C CN 1282473C
Authority
CN
China
Prior art keywords
treatment
liver
wild chrysanthemum
hours
clear paste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN 02132705
Other languages
Chinese (zh)
Other versions
CN1394635A (en
Inventor
王威
王学志
邹洪君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Shenlong Pharmaceutical Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 02132705 priority Critical patent/CN1282473C/en
Publication of CN1394635A publication Critical patent/CN1394635A/en
Application granted granted Critical
Publication of CN1282473C publication Critical patent/CN1282473C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to wild chrysanthemum granules and a preparation method. The wild chrysanthemum granules are formed by that after 500 g of hawthorn fruit, 83.3 g of chrysanthemum, 62.5 g of salt formed oriental waterplantain rhizome, 62.5 g of common selfheal fruit-spike and 83.3 g of fried cassia seed are mixed, 6332.8 g of water is added, and after the components are decocted for three hours, and medicine liquid is extracted; then 4749.6 g of water is added, and the mixture is decocted for 2 hours; medicine liquid extracted for the second time is uniformly mixed and filtered, the pressure of filtered liquid is reduced, and the filtered liquid is concentrated into clear paste with 1.30 to 1.40 (50 to 60 DEG C) of relative density. The clear paste, sugar powder and dextrin are selected, and the ratio of the clear paste to the sugar powder to the dextrin is 1:3:1; soft material is preapred from a proper amount of ethanol with 90% of concentration, after granulating and drying are carried out, and finished products are obtained. The present invention has the efficiency of calming the liver, clearing heat, cleaning head, strengthening eyesight, removing accumulation and purging, and is suitable for treating dizziness, liver-fire hyperactivity hyperlipemia, hyperlipemia, hypertension, etc. The clinically treating effect is obvious, the obvious effective rate of improving liver yang hyperactivity dizziness symptoms reaches up to 66.7%, and the total effective rate reaches up to 91.3%.

Description

The manufacture method of Wild chrysanthemum granules
(1) technical field:
The present invention relates to a kind of Chinese medicine granules, particularly a kind of have cholesterol reducing, triglyceride to hyperlipemia, improves the effect of high density lipoprotein, the Wild chrysanthemum granules that can bring high blood pressure down.
(2) background technology:
In recent years, the sickness rate of cardiovascular disease such as China's hypertension, hyperlipemia, coronary heart disease obviously rises, and how excessively gets fat because of high-strung mental work, health or long-term melancholy, angry, stagnated QI transforming into fire, due to the excessive rising of liver-YANG.At present, caused the concern of the whole society, this class disease is the first killer who threatens middle-aged and elderly people health.Hyperlipemia (being commonly called as hyperlipidemia) is the arch-criminal who causes cardiovascular and cerebrovascular disease, the sickness rate height, and China has 9,000 ten thousand people to suffer from hyperlipidemia approximately.Hyperlipidemia is abnormally dangerous, and the someone is referred to as " noiseless killer ".This is that awareness only has 25% because it is difficult for being found.Hyperlipidemia in early days and when slight almost without any sensation; the pathogenic of it is a process very slowly; usually be just to have begun period from person between twenty and fifty even child; in default of uncomfortable feeling; often can not in time find; but do not treat diseases such as can causing coronary heart disease, apoplexy, hypertension for a long time and corresponding symptom occurs, consequence is very serious.The generation of hypertension and development and hyperlipemia are closely related.Research data shows that 50% hypertensive patient is with lipid metabolic disorder, and the content of blood cholesterol and triglyceride significantly increases than the normal person, and HDL-C content is then lower.On the other hand, the also normal complicated hypertension of many hyperlipemias.At present, the drug variety of treatment cardiovascular disease is a lot, but price height, cure rate are lower, need take medicine throughout the year and keep.Up to the present also the good medicine of not finding to eradicate above-mentioned disease.
(3) summary of the invention:
The objective of the invention is at the problems referred to above provide a kind of have hyperlipemia is had cholesterol reducing, triglyceride, improve the effect of high density lipoprotein, the manufacture method of the Wild chrysanthemum granules of the effect of bringing high blood pressure down being arranged when improving blood fat.
The manufacture method of Wild chrysanthemum granules,---750g, Flos Chrysanthemi 41.65------93.75g, Spica Prunellae 31.25---Semen Cassiae 41.65 after 93.75g, the parch---124.95g of the Rhizoma Alismatis 31.25 behind 124.95g, the processed with salt that is to get Fructus Crataegi 250, add entry 4500g---8500g through mixing, decoct 1---after 6 hours, medicinal liquid is proposed.Add entry 2500g---6500g then, secondary decocts 1---and 4 hours.Secondary is carried 60 ℃) clear paste.Qinghuo reagent, Icing Sugar, dextrin, its ratio are 1: 3: 1, are that 90% an amount of ethanol is made soft material with concentration, through granulating, after the drying, being finished product.
The present invention is through verifying its clinical observation on the therapeutic effect in Traditional Chinese Medicinal College of Liaoning:
Data and method
One, case choice criteria
(1) case source:
Select 60 routine patients, wherein inpatient 53 examples account for 88.3%.Outpatient service 7 examples account for 11.7%.Age is 39---between 65 years old, and 56.6 years old mean age.Male 39 people, women 21 people, the course of disease is the longest 25 years, and is the shortest 3 months.Wherein merge coronary heart disease 10 examples, cerebral infarction sequela 2 examples, diabetes 2 examples, old heart infarction 1 example.
(2) diagnostic criteria
With reference to the hyperlipidemia diagnostic criteria of adjusting the hypolipidemic medicine regulation in " new Chinese medicine clinical research guideline " and the Ministry of Health of the People's Republic of China's in January, 1988 " clinical drug research guideline ", determine that diagnostic criteria is as follows:
1, tcm diagnosis standard
Dizzy syndrome of upper hyperactivity of liver yang
Primary symptom: dizziness and headache.
Inferior disease: 1. flushing conjunctival congestion, 2. being irritable and getting angry easily, 3. dry mouth with bitter taste, 4. constipation.
Tongue pulse condition: red tongue, yellow fur, stringy pulse.
Hold concurrently in time disease any two of all indispensable primary symptoms, a person is promptly diagnosable in the tongue pulse condition.
2, Western medicine diagnose standard:
Hyperlipidemia: serum cholesterol (TC) 〉=6.5mmol/l, or triglyceride (TG) 〉=1.6mmol/l, or high density lipoprotein (HDL-C) value, male≤1.0mmol/l, women≤1.2mmol/l all is considered as hyperlipidemia.
(3) test case standard
1, includes the case standard in
All ages that meets the Chinese and western medicine diagnostic criteria are 25---and 65 years old male and female patient are for including the test case in.
2, get rid of the case standard
1. confirm on inspection to injure causers such as oculopathy outward by intracranial spaceoccupying lesion.
2. gestation or women breast-feeding their children are to this medicine allergy sufferers.
3. merge to have the inclination, serious primary diseases such as liver, kidney and hemopoietic system, the psychotic.
4. all standards of including in that do not meet, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment and safety judgement person.
5. do not meet TCM Syndrome Type person.
Two, test method
(1) medication:
This 60 example is the treatment group, adopts the method for non-blind own control, and each 5 grams (containing crude drug amount 4 grams) secondary every day is taken after mixing it with water, and 6 weeks were a course of treatment.
MethodsThe cases enrolled must not be used other and the similar Chinese and western drugs of this medicine effect during being tried.
(2) observation index
1, health giving quality observation
1. the degree of write up vertigo change is treated front and back doing well,improving situation, the variation of body of the tongue pulse condition.
2. do serum cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, LDL inspection before and after the treatment.To observe the blood fat situation.
2, blood, routine urianlysis, liver function and serum creatinine inspection are done in safety observation before and after the treatment.To observe the safety of this medicine.
Three, curative effect determinate standard
(1) symptom curative effect determinate standard:
As follows according to " new Chinese medicine clinical research guideline " criterion:
Symptom: dizziness and headache, flushing conjunctival congestion, being irritable and getting angry easily, dry mouth with bitter taste, constipation.
Dizziness and headache: light (+)---conscious having a dizzy spell, sense of rotation or the rolling of not having self or scenery are dynamic, or simple head is murky and do not influence activity.
In (++)---conscious dizziness also has self rotation or rolling dynamic, but do not influence life or simple giddy and influence activity, but can adhere to work.
Heavy (+++)---conscious dizziness also has self or the scenery sense of rotation, and a body dare not rotate or be simple dizzy, upsets, and is difficult to competent at a job.
Flushing conjunctival congestion: light (+)---the accidental appearance
In (++)---be interrupted to occur
Heavy (+++)---often occur
Being irritable and getting angry easily: light (+)---the accidental appearance
In (++)---be interrupted to occur
Heavy (+++)---often occur
Dry mouth with bitter taste: light (+)---the accidental appearance
In (++)---be interrupted to occur
Heavy (+++)---often occur
Constipation: light (+)---the accidental appearance
In (++)---be interrupted to occur
Heavy (+++)---often occur
1, produce effects: transference cure or improve two differential above produce effects that are.
(before the treatment symptom by+, ++, treatment back symptom becomes "-".Or before the treatment symptom by +++treatment back symptom becomes "+" person.)
2, effective: more than one of doing well,improving was differential, two of less thaies are differential to be effective.(before the symptom treatment by +++after treatment, become ++ or before treating ++ become after the treatment+person.)
3, invalid; One of less than is differential to be invalid.
(2) blood fat curative effect determinate standard
As follows according to " clinical drug research guideline " criterion:
Produce effects: reach following any one person, TC descends 〉=20%, and TG descends 〉=0%, HDL-C rising 0.26mmol/l.
Effectively: TC decline 10%-<20%; TG decline 20%-<40%; HDL-C rising 0.104mmol/l-<0.26mmol/l.
Invalid: as not reach effective standard person.
Result and analysis
One, clinical symptoms curative effect
1, patient symptom observation of curative effect
Table 1 symptom curative effect summary table
The example number Produce effects Effectively Invalid Total effective rate
Example Example Example
60 40 66.7 15 25 5 8.3 91.7%
The result shows by table 1, and this medicine is 66.7% to the obvious effective rate of symptom curative effect, and total effective rate is 91.7%.
2, the relation of the course of disease and curative effect
The observation table of table 2 course of disease and curative effect
The course of disease The example number Produce effects Effectively Invalid Total effective rate
Example Example Example
In 1 year 14 8 57.2 5 35.7 1 7.1 92.9%
In 3 years 15 12 80 2 13.3 1 6.7 93.3%
More than 3 years 31 20 64.5 8 25.8 3 9.7 90.3%
By table 2 as seen, the course of disease be divided into 1 year with interior, 3 years with interior, below 3 years, total effective rate is respectively 92.9%, 93.3%, 90.3%, through X 2Check P>0.05 there was no significant difference.Illustrate that this medicine is treated vertigo, no matter course of disease length curative effect is all remarkable for liver-Yang sthenia type.
3, trip and therapeutic effect relationship
Table 3 trip and therapeutic effect relationship table
The course of treatment The example number Produce effects Effectively Invalid Total effective rate
Example Example Example
Two weeks 60 0 0 33 55 27 45 55%
All around 60 17 28.3 33 55 10 16.7 83.3%
Six weeks 60 40 66.7 15 25 5 8.3 91.7%
Annotate: two weeks with compare all around, two weeks and six weeks P<0.01 relatively.
As seen along with the increase of the course of treatment, curative effect increases by table 3, two weeks with all around, with six weeks relatively, through X 2Check P all<0.01 has significant differences, but all around with six weeks P>0.05 there was no significant differences relatively, illustrate take this medication journey should be more than all around.
4, the relation of age and curative effect
The relation of table 4 age and curative effect
Age group The example number Produce effects Effectively Invalid Total effective rate
Example Example Example
In 60 years old 30 21 70 7 23.3 2 6.7 93.3%
More than 60 years old (comprising 60 years old) 30 19 63.3 8 11.4 3 10 90%
Be respectively 93.3%, 90% by the visible two age group total effective rates of table 4, through X 2Check P>0.05 there was no significant difference illustrates that this medicine is to the difference at age, therapeutic effect no significant difference.
5, the relation of sex and curative effect
The relation of table 5 sex and curative effect
Grouping The example number Produce effects Effectively Invalid Total effective rate
Example Example Example
The man 39 27 69.2 8 20.5 4 10.3 89.7%
The woman 21 13 61.9 7 33.3 1 4.8 95.2%
By table 5 as seen, two groups of total effective rates are respectively 89.7%, 95.2%, through X 2Check P>0.05, two group there was no significant difference illustrates no matter all remarkable to the sex curative effect this medicine is.
6, clinical improvements situation before and after the treatment
Clinical improvements information slip before and after table 6 treatment
The example number Before the treatment Do not recover number after the treatment
+++ ++ + +++ ++ +
Example Example Example Example Example Example
Dizziness and headache 60 25 41.7 33 55 2 3.3 1 1.7 4 6.7 0 0
Flushing conjunctival congestion 56 18 32.1 28 50 10 17.9 0 0 2 3.6 0 0
Being irritable and getting angry easily 51 19 37.3 29 56.9 3 5.9 0 0 2 3.9 1 1.96
Dry mouth with bitter taste 57 6 10.5 38 66.7 13 22.8 0 0 1 1.8 1 1.8
Constipation 49 3 6.1 11 2.2 35 71.4 0 0 0 0 2 4.1
By table 6 as seen, each symptom all has clear improvement before and after the treatment, and it is as shown in the table not recover number after the treatment, all<0.01 significant differences is arranged with contrast P before the treatment.
Two, blood fat curative effect situation
1, blood fat curative effect
Table 7 blood fat curative effect summary table
The example number Produce effects Effectively Invalid Total effective rate
Example Example Example
60 16 26.7 23 38.3 21 35 65%
By table 7 as seen, this medicine is 26.7% to the obvious effective rate of blood fat curative effect, and total effective rate is 65%.
2, blood fat changes situation before and after the treatment
Blood fat changes information slip before and after table 8 treatment
Blood fat The example number Before the treatment After the treatment
X±SD mmol/l X±SD mmol/l
Cholesterol 9 6.95±0.48 5.89±1.14 *
Triglyceride 53 2.55±1.02 1.84±0.67 **
High density lipoprotein 22 1.85±0.23 1.02±0.31 *
Low density lipoprotein, LDL 4 5.28±0.61 3.96±1.7
Annotate: relatively preceding with treatment *P<0.05 *P<0.01
By table 8 as seen, this medicine can reduce patient's cholesterolemia, triglyceride, improves high density lipoprotein, and learning by statistics to handle has significant difference.Particularly to triglyceride reducing effect highly significant.In the face of the not obvious P of low density lipoprotein, LDL effect>0.05.
Three, blood pressure change situation before and after the treatment
Hypertensive patient's blood pressure information slip before and after table 9 treatment
Blood pressure The example number Before the treatment After the treatment
X±SD (kpa) X±SD (kpa)
Systolic pressure 31 21.71±2.04 18.45±1.89 *
Diastolic pressure 31 13.12±1.00 10.91±1.18 *
Annotate: relatively preceding with treatment *P<0.01
By table 9 as seen, by 31 routine hypertensive patients being observed treatment front and back systolic pressure and diastolic pressure, learning processing P<0.01 by statistics has significant difference to illustrate that this medicine can improve patient's systolic pressure and diastolic pressure.Has certain hypotensive effect.
Four, the tongue arteries and veins changes situation before and after the treatment
1, picture of the tongue situation of change
Table 10 picture of the tongue changes information slip
The example number Leucismus is red Red Light red
Before the treatment 60 19 41 0
After the treatment 60 12 16 32
By table 10 as seen, patient's body of the tongue is by red or dark red, transfers to light redly, illustrates that the excessive rising of liver-YANG symptom makes moderate progress.
2, pulse condition situation of change
Table 11 pulse condition situation of change table
The example number String Stringy and thready pulse Stringy and rapid pulse Heavy string
Before the treatment 60 40 8 4 8
After the treatment 60 44 6 3 7
By no significant change before and after the visible patient's of table 11 the pulse condition treatment.
Five, about poison effect of paying and untoward reaction
Information slip before and after table 12 hematuria routine, liver function, the serum creatinine treatment
Routine blood test Routine urinalysis Serum creatinine Liver function
Normally Unusually Normally Unusually Normally Unusually Normally Unusually
Before the treatment (example) 60 0 53 7 56 4 30 0
Treatment back (example) 60 0 54 6 56 4 30 0
We all do blood, routine urinalysis, liver function and serum creatinine inspection to the patient before and after the treatment, routine blood test, liver function are all in normal range before the treatment, and routine urianlysis, urine protein have+, ++ the person is totally 7 examples, the serum creatinine inspection surpasses normal value person's totally 4 examples, have after the treatment patient's urine protein by+become ± person, surplus patient's routine urinalysis serum creatinine, routine blood test, liver function have no significant change.As shown in table 12, any untoward reaction does not take place in the patient yet in the therapeutic process, and the without any side effects and untoward reaction of this medicine is described.
The present invention studies (laboratory animal provides by animal housing of Shenyang Pharmaceutical University) by pharmacodynamic experiment:
One, to the effect of cardiovascular aspect
6 of adult dog, body weight 9---10.5 kilograms, the male and female dual-purpose, Nembutal vein anesthetic (30mg/kg) after back of the body position is fixing, is opened breast.Bury the intubate dabbling drug by duodenum, lead instrument record Blood pressure of carotid artery and II leads electrocardiogram more with physiology; Take into account suitable cassette probe with Electromagnetic Flow, measure Canis familiaris L. LCA and femoral artery blood flow respectively, with the electuary consumption of being grown up a time, be converted into Canis familiaris L. by body surface area and use dosage, and be converted into the crude drug amount that is equivalent to.Experiment is divided into low dose group (0.46g/kg) and high dose group (0.92g/kg) is low, high dose group is carried out on same group of Canis familiaris L., wait to recover normal 30 minutes after, carry out high dose group and test.
19 ± 1 ℃ of laboratory room temperatures; Chart speed 15mm/Sec; Operation back artificial respirator control 200ml/min ventilation.Experimental result is as follows:
1, the exercising result to the heart coronary flow shows: low dose group administration 8 minutes, coronary flow begin to strengthen, 20---between 40 minutes effect the strongest, the highest increase by 24.8% of blood flow and relatively has significant difference (P<0.05) before the administration;
2, the common carotid artery blood pressure being influenced the result shows: low dose group is rapid-action, and administration is blood pressure lowering 15.6% after 20 minutes; High dose group was blood pressure lowering 17.3% in 40 minutes;
3, medicine does not have influence to femoral artery blood flow
4, medicine is not seen obvious change to electrocardiogram and heart rate.
21 of adult cat, body weight 2.0---2.5kg, 3 male and female dual-purposes, the sodium pentobarbital intravenous injection, (30mg/kg) anesthesia, back of the body position is fixing, by duodenum opening intubate perfusion administration, lead instrument record Blood pressure of carotid artery and II lead electrocardiogram with physiology more, be converted into cat dosage, and be converted into and be equivalent to seven of crude drug amount low dose group (0.46g/kg) and every group of cats of high dose group (0.92g/kg) with the electuary consumption of being grown up.
Laboratory temperature is 24.5 ℃, chart speed 15mm/Sec, and operation back artificial respirator control ventilation, experiment shows that two groups all have hypotensive effect, and hypotensive effect is relevant with dosage, and the rhythm of the heart and electrocardiogram are not seen obvious change blood pressure lowering.
Two, to the research of effect for reducing blood fat
Adult Wistcr rat, ♀ body weight 170-190g, ♂ body weight 180-200g is provided by animal housing of Shenyang Pharmacy College.Rat after 4 days, is divided into low dose group (0.79g/kg/ day), high dose group (1.58g/kg/ day) with normal forage feed at random, and 10 every group, male and female half and half.
The hyperlipidemia animal model: experiment beginning back 3 treated animals are thrown high lipid food, and continuous 7 days, the high lipid food prescription; Cholesterol 1.5%, cholic acid 0.25%, Adeps Sus domestica 7.5%, basic feedstuff 90.75% are made the Mus material.
Get totally 9 of (at random) 3 rats for every group before the experiment, blood is got in fasting 12h docking, survey blood fat and do the preceding control value of administration, the continuous feeding high lipid food of experimental group then, perfusion simultaneously, matched group symphysis reason saline is irritated stomach, the 8th day fasting 12h, blood is got in docking respectively, leaves standstill 40min, 3000 rev/mins of centrifugal, separation of serum mensuration.
Enzyme process is formulated T-CHOL (TC), triglyceride (TG) and high density lipoprotein (HDL), and the ENCORE-1 automatic biochemistry analyzer is measured.
The result shows that matched group gives high lipid food, and serum TC is giving under the high lipid food situation than the preceding TG rising 7% more than 4 times that raises of experiment, and serum TC, TG and matched group relatively have utmost point significant difference (P<0.01), and two groups all have the effect of the TC/HDL of reduction ratio.
In sum, draw as drawing a conclusion:
1, the present invention can cholesterol reducing and triglyceride.
2, the present invention's energy coronary blood flow increasing according to the Cor Canitis rate not being had influence and the femoral artery flow not being had effect infer, may be that specificity is expanded due to the coronary vasodilator.
3, take place from clinical disease, hyperlipidemia is to cause one of coronary heart disease principal element, coronary blood flow increasing can improve myocardial ischemia, it is antiatherogenic important indicator that TC/HDL ratio reduces, the cause and effect that The present invention be directed to incidence of coronary heart disease works, so the present invention is suitable for hyperlipidemia and coronary heart disease.
The present invention has calming liver and clearing heat, clearing eyes-improving, clearly long-pendingly rushes down turbid effect, is adapted to vertigo, liver-Yang sthenia type.Treatment hyperlipidemia, hypertension etc., and clinical efficacy is remarkable, improves obvious effective rate for the excessive risen liver-yang pattern dizziness shape to reach 66.7%, and total effective rate reaches 91.3%.And along with the increase curative effect of the course of treatment increases to some extent, two weeks with significant difference is relatively arranged all around, all around with six weeks zero differences relatively.So in taking this medicine process, should be good more than all around the course of treatment, and for gender's difference, the difference of age size and the length of the course of disease, curative effect zero difference.Effect is all remarkable, for hyperlipidemia cholesterol reducing, triglyceride is arranged, and improves the effect of high density lipoprotein.Simultaneously the patient who is accompanied with hypertension there is certain hypotensive effect when improving blood fat.
The present invention is a kind of safe and reliable, has no adverse reaction and the granule of toxic and side effects, is easy to clinically absorb, and the patient is acceptant, and is evident in efficacy.
Function cures mainly: calming liver and clearing heat, removing food stagnancy rushes down turbid.The adjuvant drug that is used for the hyperactivity of liver-fire hyperlipemia.
Usage and dosage: warm boiled water, one time 1 bag, 2 times on the one.
Specification: every packed 5g.
(4) specific embodiment:
The manufacture method of Wild chrysanthemum granules is to get Rhizoma Alismatis 62.5g, the Spica Prunellae 62.5g behind Fructus Crataegi 500g, Flos Chrysanthemi 83.3g, the processed with salt, the Semen Cassiae 83.3g after the parch, adds entry 6332.8g through mixing, decocts after 3 hours, proposes medicinal liquid.Adding entry 4749.6g secondary then decocted 2 hours.With the medicinal liquid mix homogeneously that secondary proposed, to filter, it is 1.30 that filtrate decompression is concentrated into relative density---the clear paste of 1.40 (50-60 ℃).Qinghuo reagent, Icing Sugar, dextrin, its ratio are 1: 3: 1, are that 90% an amount of ethanol is made soft material with concentration, through granulating, after the drying, being finished product.

Claims (2)

1, Wild chrysanthemum granules, the crude drug that it is characterized in that making active ingredient consists of Rhizoma Alismatis 62.5g, the Spica Prunellae 62.5g behind Fructus Crataegi 500g, Flos Chrysanthemi 83.3g, the processed with salt, the Semen Cassiae 83.3g after the parch.
2, the manufacture method of Wild chrysanthemum granules, it is characterized in that getting Rhizoma Alismatis 62.5g, the Spica Prunellae 62.5g behind Fructus Crataegi 500g, Flos Chrysanthemi 83.3g, the processed with salt, the Semen Cassiae 83.3g after the parch, add entry 4500g---8500g through mixing, decoct 1---after 6 hours, medicinal liquid is proposed, adds entry 2500g then---6500g decocts 1---4 hours, with the medicinal liquid mix homogeneously that secondary proposed, filter filtrate decompression is concentrated into 50---60 ℃ of following relative densities are 1.30---1.40 clear paste; Qinghuo reagent, Icing Sugar, dextrin, its ratio are 1: 3: 1, are 70 with concentration---95% an amount of ethanol is made soft material, after granulation, drying, is finished product.
CN 02132705 2002-07-31 2002-07-31 Wild chrysanthemum granules and preparation method Expired - Lifetime CN1282473C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 02132705 CN1282473C (en) 2002-07-31 2002-07-31 Wild chrysanthemum granules and preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 02132705 CN1282473C (en) 2002-07-31 2002-07-31 Wild chrysanthemum granules and preparation method

Publications (2)

Publication Number Publication Date
CN1394635A CN1394635A (en) 2003-02-05
CN1282473C true CN1282473C (en) 2006-11-01

Family

ID=4746897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 02132705 Expired - Lifetime CN1282473C (en) 2002-07-31 2002-07-31 Wild chrysanthemum granules and preparation method

Country Status (1)

Country Link
CN (1) CN1282473C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101816733A (en) * 2010-05-20 2010-09-01 沈阳神龙药业有限公司 Sugar-free hawthorn and chrysanthemum preparation and preparation method thereof
CN101972368B (en) * 2010-10-28 2012-11-07 赤峰天奇制药有限责任公司 Process for preparing chrysanthemum pressure-reducing granules

Also Published As

Publication number Publication date
CN1394635A (en) 2003-02-05

Similar Documents

Publication Publication Date Title
CN1239187C (en) Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method
CN1915399A (en) Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method
CN1304039C (en) Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use
CN1917895A (en) Extracts of houttuynia cordata and rubus coreanus and their composition for preventing and treating allergic diseases
CN1775274A (en) Cough-relieving sputum-resolving medicinal composition and preparing method
CN1726929A (en) Compsn. of medication for treating diabetes
CN1927331A (en) Chinese medicine preparation for curing chronic heart failure
CN1282473C (en) Wild chrysanthemum granules and preparation method
CN1478508A (en) Chinese medicinal composition for treating fatty liver and its preparation method
CN1895558A (en) Oral medicine for treating cerebral blood-supply deficiency giddiness and cava infarction and hyperthrombinemia
CN1283300C (en) Chinese traditional medicine composition for treating diabetes and preparation method thereof
CN1282470C (en) Traditional Chinese medicine for anti depression
CN1250278C (en) Oral medicine for treating dementia and feeblemindedpess
CN1650895A (en) Method of extracting medicamout having memory strengthening function from natural plant compound preparation
CN1947767A (en) Medicine for treating and preventing infantile mental retardation, and its prepn. method
CN1686302A (en) Traditional Chinese medicine for treating non-alcoholic simple fatty liver and its preparation method
CN1061256C (en) Hypertension ointment for external use
CN1742783A (en) Natural medicine preparatino for tonifying Qi strengthening body resistance and preparing method
CN1235841C (en) Method for preparing extract of peanut leaf
CN1651017A (en) Medicinal composition for treating cervical vertebra disease and its preparation method
CN1724003A (en) Health-care food with blood-sugar decreasing function, and its prepn. method
CN1857368A (en) Medicine composition for treating diabetes
CN1069537C (en) Medicine for weight-reducing and beautifying
CN1274353C (en) Medication for curing children's infantile malnutrition and preparation method
CN1824253A (en) Medicine for treating fatty liver and its preparation method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Owner name: WANG WEI

Free format text: FORMER OWNER: ZOU HONGJUN

Effective date: 20030707

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030707

Address after: Wu'ai street in Shenhe District of Shenyang City, Liaoning province 110016 No. 26-6 1-2-2

Applicant after: Wang Wei

Address before: 110141 Liaoning city of Shenyang province Shen Yuhong District Road No. 118

Applicant before: Zou Hongjun

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160726

Address after: Hunnan New District Jinhui street in Shenyang of Liaoning province 110000 City No. 9

Patentee after: SHENYANG SHENLONG PHARMACEUTICAL Co.,Ltd.

Address before: Wu'ai street in Shenhe District of Shenyang City, Liaoning province 110016 No. 26-6 1-2-2

Patentee before: Wang Wei

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20061101